Skip to main content
Journal cover image

Emerging pharmacotherapy for cancer patients with cognitive dysfunction.

Publication ,  Journal Article
Davis, J; Ahlberg, FM; Berk, M; Ashley, DM; Khasraw, M
Published in: BMC Neurol
October 24, 2013

Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of memory and cognition, with ramifications for the patient's mood and other cognition disorders. Similarly radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer's drugs memantine and donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture models to evaluate their use in treating cognitive dysfunction.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMC Neurol

DOI

EISSN

1471-2377

Publication Date

October 24, 2013

Volume

13

Start / End Page

153

Location

England

Related Subject Headings

  • Piperidines
  • Neurology & Neurosurgery
  • Neoplasms
  • Memantine
  • Indans
  • Humans
  • Donepezil
  • Cognition Disorders
  • Clinical Trials as Topic
  • Cholinesterase Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davis, J., Ahlberg, F. M., Berk, M., Ashley, D. M., & Khasraw, M. (2013). Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol, 13, 153. https://doi.org/10.1186/1471-2377-13-153
Davis, Justin, Fiona M. Ahlberg, Michael Berk, David M. Ashley, and Mustafa Khasraw. “Emerging pharmacotherapy for cancer patients with cognitive dysfunction.BMC Neurol 13 (October 24, 2013): 153. https://doi.org/10.1186/1471-2377-13-153.
Davis J, Ahlberg FM, Berk M, Ashley DM, Khasraw M. Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol. 2013 Oct 24;13:153.
Davis, Justin, et al. “Emerging pharmacotherapy for cancer patients with cognitive dysfunction.BMC Neurol, vol. 13, Oct. 2013, p. 153. Pubmed, doi:10.1186/1471-2377-13-153.
Davis J, Ahlberg FM, Berk M, Ashley DM, Khasraw M. Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol. 2013 Oct 24;13:153.
Journal cover image

Published In

BMC Neurol

DOI

EISSN

1471-2377

Publication Date

October 24, 2013

Volume

13

Start / End Page

153

Location

England

Related Subject Headings

  • Piperidines
  • Neurology & Neurosurgery
  • Neoplasms
  • Memantine
  • Indans
  • Humans
  • Donepezil
  • Cognition Disorders
  • Clinical Trials as Topic
  • Cholinesterase Inhibitors